Скачать с ютуб Workshop: Developing a Robust Evidence Package to Prepare for Market Entry в хорошем качестве

Workshop: Developing a Robust Evidence Package to Prepare for Market Entry

When you think of bringing a new therapy to market, payers, regulators, providers, and other stakeholders are requiring robust information on effectiveness as well as the overall impact of use to understand the true value for patients and impact on the wider healthcare system. Understanding what stakeholders are looking for as part of their review process is crucial to successfully develop and communicate your value message. Careful planning during clinical development is key to develop an evidence package that is useful for regulatory filing as well as discussions with payers and providers. This panel will discuss elements and generation of this evidence package Welcome Remarks: George Smith, Ph.D., Senior Director, Cell and Gene Therapy Center, IQVIA Chair: Adrian McKemey, Ph.D., SVP, Consulting Services, IQVIA Speakers: Stewart Abbot, Ph.D., Chief Operating and Scientific Officer, Adicet Bio John Doyle, Dr.P.H., VP, Global Healthcare Innovation Lead, Pfizer Manuel Duenas, VP, Market Access, Atara Biotherapeutics Felix Hsu, SVP and Global Head of Advanced Therapies, WuXi AppTec Chris McClain, VP, Sales and New Business Development, Be The Match BioTherapies Aiman Shalabi, VP, R&D, Cell and Gene Therapies, GlaxoSmithKline